IP Library Assignment 069771/0701
Patent Assignment
Reel/Frame 069771/0701

Release of Patent Security Agreements

Recorded: 2024-12-24 Pages: 48
Assignor
Assignee
ALKERMES PHARMA IRELAND LIMITED
CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, D04 C5Y6, IRELAND
Covered Properties (69)
Prodrugs of Fumarates and Their Use in Treating Various Deseases
Aripiprazole Prodrug Compositions
Application: 14/828,229 →
Publication: US 2016/0045495
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Application: 14/833,638 →
Publication: US 2016/0051546
Pharmaceutical Compositions Having Improved Storage Stability
Patent: 9,861,699 →
Application: 14/882,069 →
Publication: US 2016/0136279
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Application: 15/147,021 →
Publication: US 2016/0318869
System for Handling Communicated Threats
Application: 15/227,177 →
Publication: US 2018/0041532
Aripiprazole Formulations Having Increased Injection Speeds
Application: 15/349,243 →
Publication: US 2017/0157117
Sulfonamide and Sulfinamide Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application: 15/363,610 →
Publication: US 2017/0129851
Methods for Treating Depressive Symptoms
Application: 15/489,377 →
Publication: US 2017/0216279
Pharmaceutical Compositions Having Improved Storage Stability
Application: 15/705,237 →
Publication: US 2018/0000944
COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONIST
Application: 15/718,139 →
Publication: US 2018/0078542
Sustained Release Aminopyridine Composition
Application: 15/801,409 →
Publication: US 2018/0055774
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Application: 15/875,478 →
Publication: US 2018/0162816
Methods for Treating Antipsychotic-Induced Weight Gain
Application: 15/923,084 →
Publication: US 2018/0271855
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Application: 15/971,616 →
Publication: US 2018/0250229
Process for the Synthesis of Substituted Morphinans
Application: 15/988,498 →
Publication: US 2018/0334464
Prodrugs of Nh-Acidic Compounds
Application: 16/023,887 →
Publication: US 2019/0031648
Aripiprazole Prodrug Composition
Application: 16/024,729 →
Publication: US 2018/0318293
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Application: 16/043,721 →
Publication: US 2019/0015408
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Application: 16/131,773 →
Publication: US 2019/0084937
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application: 16/145,703 →
Publication: US 2019/0201367
Electrical Connection Structure Including Tuning Fork-Shaped Terminal
Application: 16/166,652 →
Publication: US 2019/0123466
Polymorphic Forms of Naltrexone
Application: 16/201,067 →
Publication: US 2019/0167664
Aripiprazole Formulations Having Increased Injection Speeds
Application: 16/271,248 →
Publication: US 2019/0167673
Methods for Treating Depressive Symptoms
Application: 16/272,654 →
Publication: US 2019/0167666
Sustained Release Aminopyridine Composition
Application: 16/287,575 →
Publication: US 2019/0231763
Aripiprazole Dosing Strategy
Application: 16/291,768 →
Publication: US 2019/0298716
Methods for Treating Antipsychotic-Induced Weight Gain
Application: 16/390,531 →
Publication: US 2019/0307742
Compositions of Buprenorphine and µ AntagonistS
Application: 16/394,524 →
Publication: US 2019/0247387
Aripiprazole Prodrug Composition
Application: 16/416,818 →
Publication: US 2019/0269676
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Application: 16/425,119 →
Publication: US 2019/0276406
Pharmaceutical Compositions Having Improved Storage Stability
Application: 16/425,150 →
Publication: US 2019/0275155
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application: 16/524,498 →
Publication: US 2020/0016111
Prodrugs of Nh-Acidic Compounds
Application: 16/540,802 →
Publication: US 2019/0367501
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Application: 16/595,608 →
Publication: US 2020/0108063
Naltrexone Long Acting Formulations and Methods of Use
Application: 16/656,022 →
Morphinan Derivatives with High Oral Bioavailability
Application: 16/739,262 →
Publication: US 2020/0383970
Polymer-Based Sustained Release Device
Application: 16/749,584 →
Publication: US 2020/0390891
Morphinan Derivatives for the Treatment of Drug Overdose
Application: 16/784,574 →
Publication: US 2020/0345718
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application: 16/790,849 →
Publication: US 2020/0352893
Pharmaceutical Compositions Having Improved Storage Stability
Application: 16/834,565 →
Publication: US 2020/0268891
Aripiprazole Formulations Having Increased Injection Speeds
Application: 16/889,528 →
Publication: US 2020/0289504
Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy
Application: 16/897,920 →
Publication: US 2021/0052694
Methods for Treating Antipsychotic-Induced Weight Gain
Application: 16/899,708 →
Publication: US 2021/0015812
Aripiprazole Prodrug Composition
Application: 16/904,246 →
Publication: US 2020/0316061
Methods for Treating Depressive Symptoms
Application: 16/913,404 →
Publication: US 2021/0000818
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application: 16/987,581 →
Publication: US 2021/0122758
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Application: 17/020,499 →
Publication: US 2020/0407320
Methods for Treating Antipsychotic-Induced Weight Gain
Application: 17/071,166 →
Publication: US 2021/0038594
Composition for Treating Mental Illness
Application: 17/071,236 →
Publication: US 2021/0046065
Immunomodulatory Il-2 Agents in Combination with Immune Checkpoint Inhibitors
Application: 17/072,725 →
Publication: US 2021/0163596
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Application: 17/211,352 →
Publication: US 2021/0205302
Il-2 Fusion Polypeptide Compositions and Methods of Making and Using the Same
Application: 17/315,973 →
Publication: US 2021/0371486
Il-2 Fusion Polypeptide Compositions and Methods of Making and Using the Same
Application: 17/315,974 →
Publication: US 2021/0395325
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application: 17/365,199 →
Publication: US 2022/0096419
Pharmaceutical Compositions Having Improved Storage Stability
Application: 17/398,801 →
Publication: US 2022/0072133
Aripiprazole Prodrug Composition
Application: 17/450,683 →
Publication: US 2022/0079939
Methods for Treating Antipsychotic-Induced Weight Gain
Application: 17/505,896 →
Publication: US 2022/0280502
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application: 17/547,118 →
Publication: US 2022/0356190
Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy
Application: 17/568,251 →
Publication: US 2022/0241370
Immunomodulatory Il-2 Agents in Combination with Immune Checkpoint Inhibitors
Application: 17/568,281 →
Publication: US 2022/0227868
Aripiprazole Dosing Strategy
Application: 17/665,015 →
Publication: US 2022/0152021
Aripiprazole Formulations Having Increased Injection Speeds
Application: 17/809,745 →
Publication: US 2023/0026422
Immediate Release Multilayer Tablet
Application: 17/855,242 →
Publication: US 2022/0354866
Immunomodulatory Il-2 Agents in Combination with Immune Checkpoint Inhibitors
Application: 62/916,936 →
Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy
Application: 62/924,356 →
Compositions and Methods for Cancer Immunotherapy
Application: 62/932,160 →
Methods of Purification
Application: 62/965,578 →
Compositions and Methods for Cancer Immunotherapy
Application: 63/309,199 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest Jun 25, 2014
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 033244/0523 →
Assignment of Assignor's Interest Jul 23, 2015
From: ZEIDAN, TAREK A.; DUNCAN, SCOTT; HENCKEN, CHRISTOPHER P.; WYNN, THOMAS ANDREW
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 036161/0843 →
Assignment of Assignor's Interest Oct 14, 2015
From: PERRY, JASON M.; DEAVER, DANIEL R.; HICKEY, MAGALI B.; REMENAR, JULIUS F.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 036790/0263 →
Assignment of Assignor's Interest Feb 2, 2016
From: CRESSWELL, PHILIP; PAQUETTE, SARA MONTMINY; HICKEY, MAGALI; PERKIN, KRISTOPHER
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 037643/0833 →
Security Interest May 17, 2016
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 038622/0248 →
Assignment of Assignor's Interest May 26, 2016
From: MORALES, WILFREDO, JR.; ZEIDAN, TAREK A.; CHIARELLA, RENATO A.; WRIGHT, STEVEN G.
To: ALKERMES, INC.
Reel/Frame 038728/0338 →
Assignment of Assignor's Interest Aug 3, 2016
From: JOHNSON, JESSICA ANNE
To: ROBLOX CORPORATION
Reel/Frame 039330/0676 →
Assignment of Assignor's Interest Nov 30, 2016
From: HICKEY, MAGALI B.; VANDIVER, JENNIFER
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 040460/0343 →
Security Interest Apr 4, 2017
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 041846/0029 →
Assignment of Assignor's Interest Apr 28, 2017
From: BLUMBERG, LAURA COOK; DEAVER, DANIEL R. R.; EYERMAN, DAVID J.; WYNN, THOMAS ANDREW
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 042174/0040 →
Corrective Assignment to Correct the Spelling of the Second Assignor Daniel R. Deaver Previously Recorded on Reel 042174 Frame 0040. Assignor(S) Hereby Confirms the Asignment. May 1, 2017
From: BLUMBERG, LAURA COOK; DEAVER, DANIEL R.; EYERMAN, DAVID J.; WYNN, THOMAS ANDREW
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 042380/0706 →
Assignment of Assignor's Interest Jan 23, 2018
From: REMENAR, JULIUS F.; BLUMBERG, LAURA COOK; ZEIDAN, TAREK A.
To: ALKERMES, INC.
Reel/Frame 044698/0678 →
Assignment of Assignor's Interest Jan 23, 2018
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 044698/0993 →
Assignment of Assignor's Interest Mar 22, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 045315/0812 →
Corrective Assignment to Correct the Nature of Conveyance from Assignment to Security Agreement Previously Recorded on Reel 045315 Frame 0812. Assignor(S) Hereby Confirms the Security Agreement. Mar 29, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 045789/0078 →
Assignment of Assignor's Interest Jun 27, 2018
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 046214/0599 →
Assignment of Assignor's Interest Nov 9, 2018
From: PERRY, JASON M.; DEAVER, DANIEL R.; HICKEY, MAGALI B.; REMENAR, JULIUS F.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 047461/0093 →
Security Interest Dec 3, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 047661/0244 →
Security Interest Dec 4, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 047671/0386 →
Assignment of Assignor's Interest Jan 29, 2019
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 048170/0671 →
Assignment of Assignor's Interest Jan 29, 2019
From: BLUMBERG, LAURA COOK; REMENAR, JULIUS F.; ALMARSSON, ORN; ZEIDAN, TAREK A.
To: ALKERMES, INC.
Reel/Frame 048170/0489 →
Security Interest Feb 15, 2019
From: ROBLOX CORPORATION
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 048346/0255 →
Security Interest Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
Assignment of Assignor's Interest Aug 17, 2020
From: CRESSWELL, PHILIP; PAQUETTE, SARA MONTMINY; HICKEY, MAGALI; PERKIN, KRISTOPHER
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 053513/0627 →
Release of Security Interest Feb 10, 2021
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ROBLOX CORPORATION
Reel/Frame 055221/0252 →